Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Latest Product Literature

Cavalletto L, et al. Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: a real-life cohort study. EASL HCC Summit. Geneva, Switzerland. 2017.
Gallotta A, et al. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017.

Gil-Gómez A, et al. Utility of SCCA-IgM levels in the prediction of hepatocellular carcinoma in cirrhotic patients. EASL HCC Summit. Geneva, Switzerland. 2017.
Ricco G, et al. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Dig Liver Dis. 49S:e48. 2017.

Biasiolo A, et al. Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biom Liver Dis. 1-22. 2016.

Biasiolo A, et al. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016.

Press Releases

RSS Feed Widget


Tweets by Xeptagen